Friday, Aug 21, 2026
English News
  • Hyderabad
  • Telangana
  • AP News
  • India
  • World
  • Entertainment
  • Sport
  • Science and Tech
  • Business
  • Rewind
  • ...
    • NRI
    • View Point
    • cartoon
    • My Space
    • Education Today
    • Reviews
    • Property
    • Lifestyle
E-Paper
  • NRI
  • View Point
  • cartoon
  • My Space
  • Reviews
  • Education Today
  • Property
  • Lifestyle
Home | Business | Dr Reddys To Launch Molnupiravir Next Week At Rs 35 Per Capsule

Dr Reddy’s to launch molnupiravir next week at Rs 35 per capsule

Hyderabad: Dr Reddy’s Laboratories said on Tuesday the company will launch its molnupiravir capsules 200mg under its brand name Molflu across India. The drug will be priced at Rs 35 per capsule with 10 capsules contained per strip, and the total course of 40 capsules over five days costing Rs 1,400. Molflu is expected to […]

By Telangana Today
Published Date - 4 January 2022, 07:23 PM
Dr Reddy’s to launch molnupiravir next week at Rs 35 per capsule
Dr Reddy's anti viral drug molnupiravir 'Molflu' Packshot
whatsapp facebook twitter telegram

Hyderabad: Dr Reddy’s Laboratories said on Tuesday the company will launch its molnupiravir capsules 200mg under its brand name Molflu across India.

The drug will be priced at Rs 35 per capsule with 10 capsules contained per strip, and the total course of 40 capsules over five days costing Rs 1,400.


Molflu is expected to be available from early next week in pharmacies throughout the country with particular focus on States with high caseload of Covid-19.

Earlier this year, Dr Reddy’s entered into a non-exclusive voluntary licensing agreement with Merck Sharp Dohme (MSD) to manufacture and supply molnupiravir to India and over 100 low and middle-income countries (LMICs).

Also, a Dr Reddy’s-led consortium of pharma companies collaborated to jointly sponsor, supervise and monitor the phase III clinical trial in India, and presented its findings to the Subject Expert Committee (SEC).

Last week, Dr Reddy’s received emergency-use authorisation from the Drugs Controller General of India (DCGI) to manufacture and market the oral anti-viral drug molnupiravir capsules 200mg for the treatment of adult patients with Covid-19, with SpO2 >93% and who have high risk of progression of the disease including hospitalisation or death.

Molflu will be manufactured at a USFDA-approved facility, and Dr Reddy’s has made adequate capacity preparations to ensure that it is able to help patients in need.


Now you can get handpicked stories from Telangana Today on Telegram everyday. Click the link to subscribe.

Click to follow Telangana Today Facebook page and Twitter .


  • Follow Us :
  • Tags
  • Covid-19
  • Dr Reddy’s
  • Drugs Controller General of India (DCGI)
  • Molflu

Related News

  • Odisha reports two new COVID-19 cases, total infections rise to three

    Odisha reports two new COVID-19 cases, total infections rise to three

  • Four Covid-19 patients under treatment in Kolkata as doctors urge vigilance

    Four Covid-19 patients under treatment in Kolkata as doctors urge vigilance

  • Hyderabad-based Natco, Lupin secure USFDA nod for generic breast cancer treatment

    Hyderabad-based Natco, Lupin secure USFDA nod for generic breast cancer treatment

  • Post-Covid steroid use linked to rising hip arthritis among young adults

    Post-Covid steroid use linked to rising hip arthritis among young adults

Latest News

  • Telangana HC questions govt financial priorities over welfare schemes

    4 minutes ago
  • Telangana HC refuses to stay Raidurgam land auction

    7 minutes ago
  • Indian national declared bankrupt in Singapore over unpaid wages

    40 minutes ago
  • Amit Shah to attend SSB, border security programmes in Siliguri

    58 minutes ago
  • Aisha Wahab becomes first Afghan-American elected to US Congress

    1 hour ago
  • Charter plane carrying eight crashes in western Alaska

    1 hour ago
  • NTA defends Rs 200 answer key challenge fee, says it benefits all candidates

    9 hours ago
  • Magnitude 6.7 earthquake strikes southern Peru; no damage reported

    9 hours ago

company

  • Home
  • About Us
  • Contact Us
  • Privacy Policy

business

  • Subscribe

telangana today

  • Telangana
  • Hyderabad
  • Latest News
  • Entertainment
  • World
  • Andhra Pradesh
  • Science & Tech
  • Sport

follow us

  • Telangana Today Telangana Today
Telangana Today Telangana Today

© Copyrights 2024 TELANGANA PUBLICATIONS PVT. LTD. All rights reserved. Powered by Veegam